Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 6/2017

01-12-2017 | ORIGINAL ARTICLE

Roburic Acid Suppresses NO and IL-6 Production via Targeting NF-κB and MAPK Pathway in RAW264.7 Cells

Authors: Yufen Chen, Ning Ji, Shunli Pan, Zhe Zhang, Ran Wang, Yuling Qiu, Meihua Jin, Dexin Kong

Published in: Inflammation | Issue 6/2017

Login to get access

Abstract

In the present study, we investigated the anti-inflammatory effect of roburic acid on production of nitric oxide (NO) and interlukin-6 (IL-6) in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophage cells. We found that roburic acid reduced production of NO and IL-6, and the expression of inducible nitric oxide synthases (iNOS). Meanwhile, phosphorylation of inhibitor of κBα (IκBα) and IκB kinase α/β (IKKα/β), as well as translocation of nuclear factor-κB (NF-κB) to the nucleus, was suppressed by roburic acid treatment. In addition, phosphorylation of mitogen-activated protein kinase (MAPKs) including p38 and c-Jun-NH2-terminal kinase (JNK) was inhibited. Roburic acid exhibited inhibitory activities on production of NO and IL-6 via blocking IKK/IκB/NF-κB and MAPKs pathway, suggesting the potential application as a drug candidate for therapy of inflammatory diseases.
Appendix
Available only for authorised users
Literature
1.
2.
Decano, J.L., P.C. Mattson, and M. Aikawa. 2016. Macrophages in Vascular Inflammation: Origins and Functions. Current Atherosclerosis Reports 18 (6): 34.CrossRefPubMed
3.
Gordon, S. 2007. The macrophage: past, present and future. European Journal of Immunology S9–17
4.
Guzik, T.J., R. Korbut, and T. Adamek-Guzik. 2003. Nitric oxide and superoxide in inflammation and immune regulation. Journal of Physiology and Pharmacology 54 (4): 469–487.PubMed
5.
6.
Yao, X., J. Huang, H. Zhong, N. Shen, R. Faggioni, M. Fung, and Y. Yao. 2014. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacology & Therapeutics 141 (2): 125–139.CrossRef
7.
Gabay, C. 2006. Interleukin-6 and chronic inflammation. Arthritis Research & Therapy 8 (Suppl 2): S3.CrossRef
8.
Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. International Immunology 17 (1): 1–14.CrossRefPubMed
9.
Matsuno, R., Y. Aramaki, H. Arima, Y. Adachi, N. Ohno, T. Yadomae, and S. Tsuchiya. 1998. Contribution of CR3 to nitric oxide production from macrophages stimulated with high-dose of LPS. Biochemical and Biophysical Research Communications 244 (1): 115–119.CrossRefPubMed
10.
Chen, X., S.A. Tang, E. Lee, Y. Qiu, R. Wang, H.Q. Duan, S. Dan, M. Jin, and D. Kong. 2015. IVSE, isolated from Inula japonica,suppresses LPS-induced NO production via NF-kappaB and MAPK inactivation in RAW264.7 cells. Life Sciences 124: 8–15.CrossRefPubMed
11.
Park, H.H., M.J. Kim, Y. Li, Y.N. Park, J. Lee, Y.J. Lee, S.G. Kim, et al. 2013. Britanin suppresses LPS-induced nitric oxide, PGE2 and cytokine production via NF-kappaB and MAPK inactivation in RAW 264.7 cells. International Immunopharmacology 15 (2): 296–302.CrossRefPubMed
12.
Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annual Review of Immunology 18: 621–663.CrossRefPubMed
13.
Li, X., S. Jiang, and R.I. Tapping. 2010. Toll-like receptor signaling in cell proliferation and survival. Cytokine 49 (1): 1–9.CrossRefPubMed
14.
Wang, X., S.A. Tang, R. Wang, Y. Qiu, M. Jin, and D. Kong. 2015. Inhibitory Effects of JEUD-38, a New Sesquiterpene Lactone from Inula japonica Thunb, on LPS-Induced iNOS Expression in RAW264.7 Cells. Inflammation 38 (3): 941–948.CrossRefPubMed
15.
Hommes, D.W., M.P. Peppelenbosch, and S.J. van Deventer. 2003. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 52 (1): 144–151.CrossRefPubMedPubMedCentral
16.
Wu, Li-Hong, S.W. Annie Bligh, Christine J. Leon, Xing-Shang Li, Zheng-Tao Wang, Christopher J. Branford-White, and Monique S.J. Simmonds. 2012. Chemotaxonomically significant roburic acid from Section Cruciata of Gentiana. Biochemical Systematics and Ecology 43: 152–155.CrossRef
17.
Verhoff, M., S. Seitz, M. Paul, S.M. Noha, J. Jauch, D. Schuster, and O. Werz. 2014. Tetra- and pentacyclic triterpene acids from the ancient anti-inflammatory remedy frankincense as inhibitors of microsomal prostaglandin E(2) synthase-1. Journal of Natural Products 77 (6): 1445–1451.CrossRefPubMedPubMedCentral
18.
Jin, M., S.J. Suh, J.H. Yang, Y. Lu, S.J. Kim, S. Kwon, T.H. Jo, et al. 2010. Anti-inflammatory activity of bark of Dioscorea batatas DECNE through the inhibition of iNOS and COX-2 expressions in RAW264.7 cells via NF-kappaB and ERK1/2 inactivation. Food and Chemical Toxicology 48 (11): 3073–3079.CrossRefPubMed
19.
Ghosh, S., and M. Karin. 2002. Missing pieces in the NF-kappaB puzzle. Cell 109 (Suppl): S81–S96.CrossRefPubMed
20.
Kim, E.K., and E.J. Choi. 2015. Compromised MAPK signaling in human diseases: an update. Archives of Toxicology 89 (6): 867–882.CrossRefPubMed
21.
Laskin, D.L., and K.J. Pendino. 1995. Macrophages and inflammatory mediators in tissue injury. Annual Review of Pharmacology and Toxicology 35: 655–677.CrossRefPubMed
22.
23.
Fujiwara, N., and K. Kobayashi. 2005. Macrophages in inflammation. Current Drug Targets Inflammation and Allergy 4 (3): 281–286.CrossRefPubMed
24.
Jin, M., T.C. Moon, Z. Quan, E. Lee, Y.K. Kim, J.H. Yang, S.J. Suh, et al. 2008. The naturally occurring flavolignan, deoxypodophyllotoxin, inhibits lipopolysaccharide-induced iNOS expression through the NF-kappaB activation in RAW264.7 macrophage cells. Biological & Pharmaceutical Bulletin 31 (7): 1312–1315.CrossRef
25.
Leon, C.G., R. Tory, J. Jia, O. Sivak, and K.M. Wasan. 2008. Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharmaceutical Research 25 (8): 1751–1761.CrossRefPubMedPubMedCentral
26.
Brubaker, A.L., J.L. Palmer, and E.J. Kovacs. 2011. Age-related Dysregulation of Inflammation and Innate Immunity: Lessons Learned from Rodent Models. Aging and Disease 2 (5): 346–360.PubMedPubMedCentral
27.
Pahl, H.L. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (49): 6853–6866.CrossRefPubMed
28.
Luo, J.L., H. Kamata, and M. Karin. 2005. IKK/NF-kappaB signaling: balancing life and death—a new approach to cancer therapy. The Journal of Clinical Investigation 115 (10): 2625–2632.CrossRefPubMedPubMedCentral
29.
Mohamed, M.R., and G. McFadden. 2009. NFkB inhibitors: strategies from poxviruses. Cell Cycle 8 (19): 3125–3132.CrossRefPubMed
30.
Arthur, J.S., and S.C. Ley. 2013. Mitogen-activated protein kinases in innate immunity. Nature Reviews Immunology 13 (9): 679–692.CrossRefPubMed
31.
32.
Turjanski, A.G., J.P. Vaque, and J.S. Gutkind. 2007. MAP kinases and the control of nuclear events. Oncogene 26 (22): 3240–3253.CrossRefPubMed
33.
Jia, N., Y. Li, Y. Wu, M. Xi, G. Hur, X. Zhang, J. Cui, W. Sun, and A. Wen. 2012. Comparison of the anti-inflammatory and analgesic effects of Gentiana macrophylla Pall. and Gentiana straminea Maxim., and identification of their active constituents. Journal of Ethnopharmacology 144 (3): 638–645.CrossRefPubMed
Metadata
Title
Roburic Acid Suppresses NO and IL-6 Production via Targeting NF-κB and MAPK Pathway in RAW264.7 Cells
Authors
Yufen Chen
Ning Ji
Shunli Pan
Zhe Zhang
Ran Wang
Yuling Qiu
Meihua Jin
Dexin Kong
Publication date
01-12-2017
Publisher
Springer US
Published in
Inflammation / Issue 6/2017
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-017-0636-z

Other articles of this Issue 6/2017

Inflammation 6/2017 Go to the issue

ORIGINAL ARTICLE

Crocin Attenuates Joint Pain and Muscle Dysfunction in Osteoarthritis Rat

ORIGINAL ARTICLE

Downregulation of Paralemmin-3 Ameliorates Lipopolysaccharide-Induced Acute Lung Injury in Rats by Regulating Inflammatory Response and Inhibiting Formation of TLR4/MyD88 and TLR4/TRIF Complexes

ORIGINAL ARTICLE

Anti-Dll4 Antibody Inhibits the Differentiation of Th17 Cells in Asthmatic Mice

Erratum

Erratum to: The Sesquiterpene Lactone, Budlein A, Inhibits Antigen-Induced Arthritis in Mice: Role of NF-κB and Cytokines

ORIGINAL ARTICLE

Melatonin Attenuates Pain Hypersensitivity and Decreases Astrocyte-Mediated Spinal Neuroinflammation in a Rat Model of Oxaliplatin-Induced Pain

ORIGINAL ARTICLE

Lipoxin A4 Attenuates Bronchopulmonary Dysplasia via Upregulation of Let-7c and Downregulation of TGF-β1 Signaling Pathway

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits